Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:

NCT ID: NCT04680273 Completed - Healthy Volunteers Clinical Trials

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential

Start date: January 7, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label, single-center, two part study in healthy female subjects of non-childbearing potential to investigate the absorption, metabolism, and excretion of [14C]-GDC-9545 (Part 1), the absolute bioavailability of formulations F12 and F18 (i.e., GDC-9545/F12 capsule, 30 mg and GDC-9545/F18 capsule, 30 mg) and relative bioavailability of GDC-9545 oral capsule F18 to the F12 formulation (Part 2). It is planned that Part 1 will begin prior to Part 2 of the study, and that the two parts of the study will partially overlap.

NCT ID: NCT04679909 Completed - Healthy Volunteers Clinical Trials

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

Start date: February 25, 2021
Phase: Phase 1
Study type: Interventional

A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.

NCT ID: NCT04679493 Completed - Healthy Volunteers Clinical Trials

Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers

Start date: December 17, 2020
Phase: Phase 1
Study type: Interventional

A double-blind, randomized, placebo-controlled, Phase I clinical study of the safety, tolerability and pharmacokinetics (PK) of ascending doses of XC7 after single and multiple oral administration in healthy volunteers. It's planned to include sequentially 2 cohorts of 4 volunteers who will receive a single dose of XC7 (100 mg and 200 mg) or placebo (cohort ratio 3:1) and 1 cohort of 8 volunteers who will receive multiple doses of the XC7 (200 mg) or placebo during 14 days (cohort ratio 6:2).

NCT ID: NCT04676906 Completed - Healthy Volunteers Clinical Trials

A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds

Start date: November 26, 2020
Phase: Phase 1
Study type: Interventional

People with type 2 diabetes have too much sugar in their blood and need treatment to control their sugar level. The 3 study compounds in this study are similar to an approved antidiabetic medicine that helps to lower blood sugar levels in people with type 2 diabetes. This approved antidiabetic medicine is generally safe and well tolerated. The study compounds are expected to have the same antidiabetic effect as the approved medicine. The purpose of this study is to investigate how quickly and to what extent each of the 3 study compounds are broken down in the body (this is called pharmacokinetics). The dose of each study compound will be very low (this is called a microdose), and will be labelled with a small amount of carbon-14. This is radioactive, and it makes it possible to track the study compound in the blood. The 3 study compounds in this study have not been given to humans before. The study will be performed in up to 18 healthy male volunteers. The study will consist of 3 groups of 6 volunteers each. Each participant will receive only one dose of study medicine.

NCT ID: NCT04676685 Completed - Healthy Volunteers Clinical Trials

A Study to Assess the Safety and Tolerability of E2730 After Multiple Dose and the Food Effect After Single Dose in Healthy Participants

Start date: December 16, 2020
Phase: Phase 1
Study type: Interventional

The primary purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of E2730 of multiple ascending oral doses in healthy adult participants and to assess the differences in PK, safety, and tolerability of E2730 between healthy Japanese and non-Japanese participants following multiple doses. This study will also determine the effect of food on PK of E2730.

NCT ID: NCT04667156 Completed - Healthy Volunteers Clinical Trials

Study to Investigate Relative Bioavailability of Different Formulations of SHR6390 in Healthy Subjects

Start date: December 13, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate relative bioavailability during the new and traditional formulations of SHR6390 in healthy subjects

NCT ID: NCT04665154 Completed - Healthy Volunteers Clinical Trials

A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers

MAS-FIH
Start date: June 7, 2019
Phase: Phase 1
Study type: Interventional

The study is conducted to investigate the safety, tolerability and pharmacokinetics of MAS825 in healthy volunteers.

NCT ID: NCT04663464 Completed - Healthy Volunteers Clinical Trials

Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.

Start date: November 16, 2020
Phase: Phase 1
Study type: Interventional

A study to evaluate and compare the PK profiles of abaloparatide-SC 80 μg and abaloparatide-sMTS 300 μg in a cohort of healthy men and to make a similar evaluation in a cohort of healthy women

NCT ID: NCT04657042 Recruiting - Lung Cancer Clinical Trials

4D-MRI for Precision Medicine

Start date: November 5, 2020
Phase:
Study type: Observational

The purpose of this study is to develop new ways to make medical images of the lungs and liver of adults using a technique called four-dimensional magnetic resonance imaging (4D-MRI). This technique produces three-dimensional movies of the inside of the chest and abdomen while the patient is breathing. (The fourth dimension is time!) This new way of medical imaging is being developed to help cancer patients undergoing radiation therapy. Radiation therapy is used to treat cancerous tumors. For radiation therapy to be effective, the precise size, shape, and location of the tumor within the body must be known. A particular difficulty for radiation treatment of lung and liver cancer is that the tumor moves during treatment because the patient is breathing. Therefore, tumor motion must also be incorporated into the treatment plan. This study aims to improve radiation treatment planning through better targeting and dose estimation based on 4D-MRI. Before this new imaging method can be used for radiation treatment planning, it must be tested in living, breathing volunteers.

NCT ID: NCT04655898 Completed - Healthy Volunteer Clinical Trials

Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects

Start date: December 16, 2020
Phase: Phase 1
Study type: Interventional

This is a clinical pharmacology study to characterize the biotransformation and excretion of [14C]CC-90001 and to evaluate the safety and tolerability of [14C]CC-90001 following a single oral dose of [14C]CC-90001 in healthy male subjects. Approximately 8 subjects will be enrolled into the study with a goal of 6 subjects being eligible for analysis.